Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - As part of the new federal budget announced May 11, Medicines Australia has negotiated price-saving measures with the Australian government that will cut prices on off-patent medicines in exchange for an assurance from the government that innovative prices on drugs will not be cut for four years

You may also be interested in...



Will More Subsidies For New Drugs Be A Core Promise Of New Australian Government?

A new government in Australia faces a budget gap that will soon bring health care reimbursement with industry focused on a pledge by the Liberal Party to restore the independence of the Pharmaceutical Benefits Advisory Committee.

What Impact Will Sept. 7 Australian Election Have On Pharma Industry?

Australia’s Federal Election is on Sept. 7, and both Medicines Australia and AusBiotech have been lobbying the Labor and the Liberal National parties to see what the incoming government can offer the pharmaceutical, medical device and biotechnology industries.

Medicines Australia Says PBS Reforms Are Keeping Drug Prices Lower

Industry group Medicines Australia attempts to refute a study that says the payment structure of the Pharmaceutical Benefits Scheme is approaching an unsustainable level.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel